AGL40.21▲ 0.18 (0.00%)AIRLINK127.64▼ -0.06 (0.00%)BOP6.67▲ 0.06 (0.01%)CNERGY4.45▼ -0.15 (-0.03%)DCL8.73▼ -0.06 (-0.01%)DFML41.16▼ -0.42 (-0.01%)DGKC86.11▲ 0.32 (0.00%)FCCL32.56▲ 0.07 (0.00%)FFBL64.38▲ 0.35 (0.01%)FFL11.61▲ 1.06 (0.10%)HUBC112.46▲ 1.69 (0.02%)HUMNL14.81▼ -0.26 (-0.02%)KEL5.04▲ 0.16 (0.03%)KOSM7.36▼ -0.09 (-0.01%)MLCF40.33▼ -0.19 (0.00%)NBP61.08▲ 0.03 (0.00%)OGDC194.18▼ -0.69 (0.00%)PAEL26.91▼ -0.6 (-0.02%)PIBTL7.28▼ -0.53 (-0.07%)PPL152.68▲ 0.15 (0.00%)PRL26.22▼ -0.36 (-0.01%)PTC16.14▼ -0.12 (-0.01%)SEARL85.7▲ 1.56 (0.02%)TELE7.67▼ -0.29 (-0.04%)TOMCL36.47▼ -0.13 (0.00%)TPLP8.79▲ 0.13 (0.02%)TREET16.84▼ -0.82 (-0.05%)TRG62.74▲ 4.12 (0.07%)UNITY28.2▲ 1.34 (0.05%)WTL1.34▼ -0.04 (-0.03%)

Global equities edge higher

Share
Tweet
WhatsApp
Share on Linkedin
[tta_listen_btn]

NEW YORK Global equity benchmarks edged higher on Friday as investors weighed a slight gain in oil against concerns that further stimulus measures by the European Union to combat the economic damage from the coronavirus pandemic could be delayed until next year. Safe-haven assets such as the dollar and government bonds were flat, reflecting the market’s unsettled direction. MSCI’s All Country World Index gained 0.18% following modest declines in Asia and Europe. The index is on pace for its worst weekly performance since March. Equity markets gave up their gains on Thursday after a report that Gilead Sciences Inc’s antiviral drug remdesivir had failed to help severely ill COVID-19 patients in its first clinical trial. “Any piece of bad news is likely to rattle the market,” said Tim Ghriskey, chief investment strategist at New York-based wealth management firm Inverness Counsel. “Investors are keen for a semblance of hope that they can soon crawl out of their homes and get on with some form of normal life, even if with trepidation and fear.”—Reuters

Related Posts